Production and process controls, organization and personnel were the top problems found, while packaging and labeling citations increased in 2017 and 2018.
Naheed Sayeed
Advertisement
Articles by Naheed Sayeed
Advertisement
Latest Updated Articles
- Lessons from FDA 483s and cGMP Inspection Data
December 15th 2019
Advertisement
Advertisement
Trending on BioPharm International
1
FDA Reportedly Pauses National Priority Voucher Pilot and Pauses CRL Publication
2
Zai Lab’s Long-Acting Atopic Dermatitis Bispecific Points to Every-12-Week Dosin
3
What 3 Principles Guide Merck's Biologics and ADC Capacity Placement?
4
FDA Grants Kamau RMAT Designation to Nula-cel for Sickle Cell Disease
5